Zimmer Biomet Holdings, Inc. ZBH
Verdict: Hold. Fair value $102 against a price of $92.85 on 12 Jan 2026, 10% above the price.
In plain words
The case for: Narrow competitive moat provides durability. Market leadership enables pricing power. Industry tailwinds with growing market.
The case against: Intense competitive pressure could compress margins. Long-term debt increased from $4.87B to $5.34B (+9.7%) while Net Income declined.. Gross Margin Index (GMI) of 1.005 indicates slight deterioration in margins year-over-year..
Main risks
- Thin revenue cushion: 0.3% decline causes EBIT loss
- Management recently lowered guidance
- Extremely high Days Inventory Outstanding (456 days) ties up massive capital
- Low Return on Equity (6.3%) indicates inefficient leverage of shareholder capital
- Anemic revenue growth (4% CAGR) lags broader MedTech sector
- Intense competitive environment